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Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose co-transporter 2 (SGLT2) inhibitors are frequently used in combination for the treatment of type 2 diabetes mellitus (T2DM).
We examined the efficacy and safety of teneligliptin (a DPP-4 inhibitor) added to canagliflozin (an SGLT2 inhibitor) monotherapy in Japanese patients with poorly controlled T2DM as part of the development of a fixed-dose combination of teneligliptin and canagliflozin.
Japanese patients treated with canagliflozin (100 mg) for ≥12 weeks were randomized to receive add-on teneligliptin (20 mg; C + T group) or placebo (C + P group) for 24 weeks. The primary endpoint was change in glycated haemoglobin (HbA1c) from baseline to Week 24. The between-group differences in reductions from baseline to Week 24 were significantly greater in the C + T group for HbA1c (−0.94%; P < .001). The incidence of adverse events was similar in both groups (55.8% and 49.4% in the C + T and C + P groups, respectively). No episodes of hypoglycaemia were reported. Teneligliptin added to ongoing canagliflozin monotherapy improved glycaemic control and was well tolerated in Japanese patients with inadequately controlled T2DM. 1 Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce urinary glucose reabsorption by inhibiting SGLT2, lower plasma glucose in an insulin-independent manner and help to alleviate glucose toxicity. They are also expected to improve insulin resistance by alleviating glucose toxicity and decreasing body weight. 2, 3 The independent mechanisms of action of these drugs and the low risk of hypoglycaemia provide support for combination therapy as a therapeutic option. Indeed, prior studies have demonstrated
| Study design and treatments
The study comprised a 4-week run-in period, a 24-week double-blind treatment period, and a 2-week post-treatment observation period ( Figure S1 ). All patients received canagliflozin at a dose of 100 mg (the approved dose in Japan) once daily before breakfast during the run-in period, treatment period and post-treatment observation period. At the start of the treatment period, patients were randomized in a 1:1 manner to receive placebo (C + P group) or teneligliptin (C + T group) at a dose of 20 mg once daily before breakfast.
Randomization was performed using the permuted block method.
Diet and exercise therapy was to continue unchanged throughout the trial.
| Primary efficacy and safety endpoints
The primary efficacy endpoint was the change in HbA1c from baseline to the end of the treatment period. The safety of C + T and C + P was assessed in terms of adverse events (AEs), hypoglycaemia, laboratory variables (haematology, blood biochemistry and urinalysis), electrocardiography and vital signs. AEs were evaluated in terms of their seriousness and relationship to the study drugs. AEs and drugrelated AEs were classified according to the System Organ Class and Preferred Term using the MedDRA version 18.1J.
3 | RESULTS
| Patient disposition and baseline characteristics
A total of 213 patients were initially enrolled, of whom 59 discontinued before the treatment period ( Figure S2) ; therefore, 154 patients were randomized, with 77 patients per group. Patient characteristics are shown in Table S1 , Appendix S1.
| Efficacy variables
The primary endpoint, the LS mean AE SE (baseline value as covariate) change in HbA1c from baseline to Week 24 (LOCF) was 0.00% AE 0.08% and −0.94% AE 0.08% in the C + P and C + T groups, respectively, with a significant between-group difference of −0.94% AE 0.11% (P < .001, two-sided ANCOVA as specified in the protocol) (Table S2 , Appendix S1). As illustrated in Figure 1 , HbA1c started to decrease within 4 weeks of treatment in the C + T group and continued to decrease through to Week 12, and the reduction was sustained until the end of treatment. By contrast, HbA1c remained broadly unchanged in the C + P group. Significantly greater FIGURE 1 Changes in HbA1c from baseline to each visit during the 24-week treatment period, and at the last observation carried forward. Values are expressed as the least squares mean AE standard error. The least squares mean was determined by analysis of covariance with treatment group as a fixed factor and the baseline value as a covariate. *P < .001 for the C + T group vs C + P group at all time points. C + P, canagliflozin plus placebo; C + T, canagliflozin plus teneligliptin; HbA1c, glycated haemoglobin; LOCF, last observation carried forward; LS mean, least squares mean proportions of patients in the C + T group than in the C + P group achieved HbA1c <7.0% (50.00% vs 8.11%, respectively; P < .001) or <8.0% (75.76% vs 18.42%, respectively; P < .001, 2-sided Fisher's exact test as specified in the protocol) at Week 24 (LOCF). Table S2 (Appendix S1) shows the changes in other efficacy endpoints from baseline to Week 24 (LOCF). Supporting the change in HbA1c, the reduction in FPG was significantly greater in the C + T group, with a between-group difference of −15.6 AE 3.9 mg/dL (LS mean AE SE, P < .001, two-sided ANCOVA [baseline value as covariate] as specified in the protocol). The absolute and percent changes in body weight were 0.11 AE 0.20 kg and 0.09% AE 0.29%, respectively, in the C + T group vs −0.98 AE 0.20 kg and −1.34% AE 0.29%, respectively, in the C + P group. The betweengroup differences in changes in body weight were 1.09 AE 0.29 kg and 1.43% AE 0.41% (both P < .001), respectively. Additional efficacy results and the results of a mixed-meal tolerance test are included in Appendix S1 (Results). Table 1 shows the incidence of AEs, including AEs of special interest in both groups. AEs and drug-related AEs occurred in 49.4% and 14.3% of patients, respectively, in the C + P group and in 55.8% and 6.5% of patients, respectively, in the C + T group. Serious AEs occurred in 2.6% and 1.3% of patients in the C + P and C + T groups,
| Safety
respectively. There were no serious drug-related AEs in either group.
AEs led to discontinuation and drug-related AEs led to discontinuation in 3.9% and 1.3% of patients, respectively, in the C + P group.
There were no AEs leading to treatment discontinuation in the C + T group. In terms of AEs of special interest, there were no episodes of hypoglycaemia in either group. Gastrointestinal disorders (11.7% vs 7.8%) and skin and subcutaneous tissue disorders (10.4% vs 5.2%)
were more common in the C + T group than in the C + P group.
Malignant neoplasms occurred in 2.6% of patients in the C + P group and in no patients in the C + T group. Other AEs of clinical relevance occurred in ≤2 patients in each group. <7.0% or <8.0%. These improvements were consistent with those observed in earlier clinical trials in which teneligliptin was added to oral hypoglycaemic drugs other than SGLT2 inhibitors. [14] [15] [16] In fasting conditions, the fasting proinsulin/C-peptide ratio was reduced and In this trial, the change in body weight from baseline to Week 24 was −0.98 kg in the C + P group and 0.11 kg in the C + T group.
| DISCUSSION
The change in urinary glucose/creatinine ratio from baseline was lower in the C + T group compared with the C + P group, probably because of the glucose-lowering effect of teneligliptin. This result suggests that calorie loss through glucose excretion was lower in the C + T group than in the C + P group throughout the treatment period. Furthermore, some meta-analyses and clinical trials of teneligliptin have reported that DPP-4 inhibitors negligibly increase body weight, probably as a result of enhanced insulin-stimulated glucose uptake. 15, 16, [18] [19] [20] The present trial also examined the safety of teneligliptin added to ongoing canagliflozin therapy. Of note, there were no serious Gastrointestinal disorders 6 (7.8) 9 (11.7)
Abbreviations: C + P, canagliflozin plus placebo; C + T, canagliflozin plus teneligliptin; AE, adverse event.
a In females only (n = 19).
